Sopharma stock: September sales rose 13 percent. Sopharma stock faces October 30 vote

Published on 10/22/2026 at 01:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

September sales increased 13 percent year on year, with domestic sales up 20 percent. Sopharma stock faces an October 30 vote on a EUR 0.052 dividend.

Cash return and operating growth

Sopharma reported September sales growth of 13 percent on October 20, 2026.
First-half 2026 consolidated profit reached EUR 50.8 million, up 41 percent year on year.
Shareholders will vote on October 30, 2026, on a EUR 0.052 interim dividend.

Sopharma, BG11SOSOBT18, Illustration mit AI erstellt.

Sopharma reported a 13 percent year-on-year increase in September sales, while domestic sales grew 20 percent and exports rose 8 percent. Investing.com reported the figures on October 20, 2026, covering the period from September 1 through September 30.

Growth broadens beyond exports

The September result adds to a stronger cumulative picture. Sopharma had reported 43 percent sales growth through August 2026, including 68 percent growth in exports and 3 percent growth in domestic sales, according to Bankier.pl on September 21, 2026. The latest monthly figures therefore show a more balanced geographic contribution than the year-to-date mix.

For the first half of 2026, consolidated sales reached EUR 730 million, up 11 percent from the prior-year period, while consolidated profit rose 41 percent to EUR 50.8 million. Investor.bg reported those figures on September 26, 2026.

What does the dividend mean?

The proposed interim dividend is EUR 0.052 per share, based on the first-half 2026 financial report. That cash distribution is the central shareholder question ahead of the extraordinary meeting, but the proposal still requires a vote.

Three dated operating signals

On September 21, 2026, Sopharma reported 43 percent sales growth through August, including 68 percent export growth, according to Bankier.pl. On September 26, 2026, Investor.bg reported the EUR 0.052 interim dividend proposal. On October 20, 2026, Investing.com reported 13 percent September sales growth.

Two dates shape the next step

The extraordinary general meeting is scheduled for October 30, 2026, with November 20, 2026, set as the fallback date if a quorum is not reached. Money.pl reported that the agenda includes approval of the first-half report and a decision on the interim dividend.

Market value and shareholder decision

Sopharma's market capitalization stood at EUR 1.6 billion as of October 21, 2026. The next material event is the October 30 vote, where the proposed EUR 0.052 payment will be considered alongside the first-half report. The further course of trading is shown by the continuously updated real-time quote of Sopharma stock.